China Jails Japanese Pharma Executive Over Espionage Charge

A Chinese court sentenced Hiroshi Nishiyama, a senior executive at Japan’s Astellas Pharma, to three and a half years in prison on charges of espionage, Tokyo confirmed on Wednesday. The conviction of Nishiyama, detained since March 2023, has further heightened diplomatic tensions between Japan and China while fueling fears over the safety and legal risks facing foreign business figures in China.

Executive Detained Under Broad Espionage Law

Nishiyama, a veteran representative of Astellas Pharma in China, was accused under China’s increasingly expansive national security legislation. The country’s amended espionage law, which took effect in 2023, has broadened the definition of spying and increased the scope of state scrutiny over both domestic and foreign entities.

No specifics about the accusations or trial proceedings have been made public. His detention and subsequent sentencing have been widely seen as part of a growing trend of secretive legal actions targeting foreign nationals.

Business Community Alarmed, Tokyo Responds

Japanese officials, including Ambassador Kenji Kanasugi, expressed concern during a press briefing in Beijing following the court ruling. The Japanese government has demanded transparency and the protection of legal rights for its citizens abroad.

This case follows a pattern of detentions involving foreign businesspeople, sparking fear within the international business community. Analysts note that the chilling effect of China’s security laws is becoming a significant factor in corporate risk assessments.